XM does not provide services to residents of the United States of America.

Future Pak raises cash portion of buyout offer for Vanda



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Future Pak raises cash portion of buyout offer for Vanda</title></head><body>

Adds Vanda's comment in paragraph 4, updates shares in paragraph 5

June 13 (Reuters) -Contract manufacturer Future Pak said on Thursday it has raised the cash portion of its buyout offer as part of a final attempt to acquire Vanda Pharmaceuticals VNDA.O.

It raised the portion to $8.50-$9.00 per share alongside previously proposed contingent value rights amounting to about $4.27 per share. It had previously offered $7.25 to $7.75 per share in cash for Vanda.

The privately held company said it "requires constructive engagement" from Vanda by June 26 or it will withdraw the offer.

Vanda said it would evaluate the revised, non-binding proposal to determine its action in the best interests of the company and its shareholders.

The latest bid represents a more than two-fold premium to Vanda's last closing price of $5.92. Shares of the Washington-based drugmaker rose more than 9% to $6.47 in morning trading.

Vanda had rejected the earlier proposal, saying it significantly undervalued the company and was not in the best interest of the firm and its shareholders.

Last Thursday, UK-based Cycle Pharmaceuticals also extended an offer to acquire the drugmaker for $8 per share, representing a total cash consideration of $466 million.

Future Pak's offer included contingent value rights, which could provide additional benefits to Vanda shareholders if certain performance targets are met.

Rights-based targets include sales-based payments for Vanda's schizophrenia drug Fanapt. Targets also included $200 million of any license proceeds for Vanda's experimental drug, tradipitant, used to treat of paralysis of the stomach.

The U.S. health regulator is set to decide on tradipitant by Sept. 18.



Reporting by Sriparna Roy in Bengaluru; Editing by Sonia Cheema, Arun Koyyur and Shailesh Kuber

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.